IntrinsicIntrinsic
← All summaries

IDEXX LABORATORIES INC /DE

IDXX
Financials & Chart →

Business Summary

IDEXX Laboratories operates in the companion animal veterinary diagnostics, livestock, poultry and dairy diagnostics, and water testing industries. The company develops, manufactures, and distributes products and provides services primarily for these three industries, and also manufactures and sells human medical point-of-care diagnostic products. The companion animal healthcare industry is highly competitive, with IDEXX competing against companies such as Mars, Incorporated brands Antech Diagnostics and Heska, and Zoetis Inc. in North America, and against Zoetis Inc., Mars brands, Fujifilm Holdings Corporation, Arkray, Inc., Mindray, and BioNote, Inc. in certain international geographies. In water, livestock, poultry and dairy testing, competitors include Neogen Corporation, Charm Sciences, Inc., BioChek, Innovative Diagnostics, and Thermo Fisher Scientific Inc. In veterinary software and diagnostic imaging, the largest competitor in North America and the U.K. is Covetrus, Inc., with numerous smaller companies also competing. IDEXX competes primarily on the basis of ease of use, speed, diagnostic accuracy, product quality, breadth of product line, differentiated innovation, fully integrated technology, information management capability, and the quality of technical and customer service.

IDEXX's competitive positioning is built on providing veterinarians with the highest quality diagnostic information, software products and services, and medical evidence to support advanced medical care. The company believes the breadth of its full diagnostic solution, including novel products and services developed and made available only by IDEXX, as well as the software integration of its offering, provides a differentiated competitive advantage. IDEXX differentiates its point-of-care instruments based on time-to-result, ease-of-use, throughput, breadth of diagnostic menu, accuracy, reliability, and integration with the IDEXX VetLab Station and VetConnect PLUS. The company seeks to differentiate its SNAP rapid assay tests based on critically important sensitivity and specificity demonstrated by peer-reviewed third-party research, and its reference laboratory services on a differentiated test menu, technology, quality, turnaround time, and customer service. IDEXX also differentiates its practice management systems through enhanced functionality, ease-of-use, and embedded integration with point-of-care instruments and reference laboratory test results.

IDEXX generates revenue through a mix of recurring and non-recurring income. Recurring revenue, which accounted for approximately 79% of consolidated revenue for the year ended December 31, 2025, is derived from IDEXX VetLab consumables, SNAP rapid assay test kits, reference laboratory diagnostic and consulting services, extended maintenance agreements, accessories, and veterinary software subscriptions. Non-recurring revenue comes from capital placements of point-of-care instruments, diagnostic imaging systems, and practice management systems hardware. The company's primary customer segments are veterinarians for the Companion Animal Group (CAG) segment, government laboratories and water utilities for the Water segment, and livestock and poultry producers and government laboratories for the Livestock, Poultry and Dairy (LPD) segment. IDEXX's platform ecosystem integrates point-of-care analyzers, reference laboratory services, and information management technologies like the IDEXX VetLab Station and VetConnect PLUS, providing a comprehensive view of patient diagnostic information.

The Companion Animal Group (CAG) segment provides diagnostic and information management products and services for the companion animal veterinary industry. CAG Diagnostics includes point-of-care diagnostic solutions such as the IDEXX VetLab suite of analyzers (Catalyst One, ProCyte One, SediVue Dx, IDEXX inVue Dx) and SNAP rapid assay test kits, as well as reference laboratory diagnostic and consulting services through a network of approximately 80 laboratories. CAG Diagnostics recurring revenue was $3,407,199,000 for the year ended December 31, 2025, comprising IDEXX VetLab consumables of $1,496,752,000 , rapid assay products of $348,950,000 , reference laboratory diagnostic and consulting services of $1,424,073,000 , and CAG Diagnostics services and accessories of $137,424,000 . CAG Diagnostics capital instruments revenue was $200,206,000 . Veterinary Software, Services, and Diagnostic Imaging Systems revenue was $345,880,000 , with recurring revenue of $276,338,000 and systems and hardware of $69,542,000 . The Water segment provides innovative testing solutions for detection of microbiological parameters in water, with principal products including Colilert, Colilert-18, Colisure, Enterolert, Pseudalert, Filta-Max, Legiolert, Quanti-Tray products, and IDEXX Tecta systems. Water segment revenue was $201,149,000 for the year ended December 31, 2025. The Livestock, Poultry and Dairy (LPD) segment provides diagnostic tests, services, and instrumentation for livestock and poultry health, including tests for Bovine Viral Diarrhea Virus, Porcine Reproductive and Respiratory Syndrome, and Transmittable Spongiform Encephalopathies, as well as dairy products like SNAP Beta-Lactam ST and SNAPduo ST Plus. LPD segment revenue was $131,787,000 for the year ended December 31, 2025.

The Other operating segment, which combines human medical diagnostic products and out-licensing arrangements, reported revenue of $17,481,000 for the year ended December 31, 2025. IDEXX's point-of-care analyzers, including the Catalyst One, ProCyte One, SediVue Dx, and IDEXX inVue Dx, utilize proprietary AI capabilities in their image capture systems. The IDEXX inVue Dx Cellular Analyzer, launched in late 2024, automates real-time cytology and blood cell morphology testing using advanced optics and AI technology. VetConnect PLUS is a cloud-based technology that enables veterinarians to access and analyze patient data from all IDEXX diagnostic modalities, incorporating IDEXX DecisionIQ which utilizes proprietary technology including AI. IDEXX Telemedicine provides specialized veterinary consultation services accessed through IDEXX Web PACS, ezyVet, and VetMedStat. The company's practice management system offerings include cloud-based ezyVet, Animana, and IDEXX Neo, and on-premises Cornerstone. Diagnostic imaging systems include the IDEXX ImageVue DR50 and IDEXX ImageVue DR30, with the IDEXX ImageVue DR50 Plus launching in North America in January 2026.

During the year ended December 31, 2025, IDEXX launched the IDEXX Cancer Dx Panel in North America, a simple blood test for dogs that screens for lymphoma, and plans to expand the panel to include canine mast cell tumor detection in North America in 2026. The company also launched the UV Viewer Plus in 2025, a bench-top UV light cabinet for water testing. In September 2025, IDEXX acquired a customer relationship intangible asset of a privately-owned reference laboratory in the U.S. for approximately $15.6 million , including an estimated contingent payment of $2.3 million . During the first quarter of 2024, the company acquired the assets of a privately-owned software and data platform business for approximately $81.1 million . IDEXX repurchased approximately 2.4 million shares of its common stock during the year ended December 31, 2025, for $1,216,964,000 . The company repaid in full upon maturity its 2025 Series C Notes for $103.4 million and its 2025 Series B Notes for $75.0 million . Research and development expenses were $251.2 million for the year ended December 31, 2025.

For the year ended December 31, 2025, IDEXX reported total revenue of $4,303,702,000 , an increase of 10.4% compared to $3,897,504,000 in the prior year. Net income was $1,059,464,000 , compared to $887,867,000 in 2024. Diluted earnings per share were $13.08 versus $10.67 in the prior year. Gross profit margin increased to 61.8% from 61.0% in 2024. Income from operations was $1,360,031,000 , compared to $1,128,337,000 in the prior year. Net cash provided by operating activities was $1,181,805,000 for the year ended December 31, 2025, compared to $929,001,000 in 2024.

Business Outlook

IDEXX provided its projected effective tax rate for 2026 of approximately 21.3% . The company also provided its initial 2026 financial outlook, which anticipates a similar decline in U.S. same-store clinical growth levels as in 2025, reflecting near-term sector and macroeconomic dynamics. IDEXX currently anticipates a 1% to 2% reduction in diluted shares through share repurchases in 2026, subject to market conditions. The company anticipates that year-over-year changes in foreign exchange rates will increase revenues, operating profit, and diluted earnings per share in the year ending December 31, 2026, by approximately $28 million , $22 million , and $0.22 per share, respectively, including net year-over-year impacts of foreign currency hedging activity expected to increase total company operating profit by approximately $4 million and diluted earnings per share by $0.04 .

IDEXX's growth strategy includes expanding its diagnostic test menu and introducing new products. The company launched the IDEXX Cancer Dx Panel in North America during 2025, a simple blood test for dogs that screens for lymphoma, and will expand the panel to include canine mast cell tumor detection in North America in 2026. IDEXX currently anticipates launching the IDEXX Cancer Dx test for canine lymphoma internationally in the first half of 2026. The company also launched the IDEXX ImageVue DR50 Plus in North America in January 2026, which combines high definition, AI-powered imaging with a lower dose of radiation. IDEXX continues to invest in developing new products and services, with research and development expenses of $251.2 million for the year ended December 31, 2025, representing 5.8% of consolidated revenue. The company's strategy includes developing and introducing new or improved innovative diagnostic tests and services for both reference laboratories and point-of-care applications, and developing new or improved innovative, data-insightful software solutions.

IDEXX's growth also focuses on geographic expansion and increasing international sales. For the year ended December 31, 2025, approximately 36% of overall revenue was attributable to sales to customers outside the U.S. The company intends to continue to expand its international operations and business. In the Water segment, future growth is expected to be partially dependent on the ability to increase international sales. IDEXX also seeks to expand its reference laboratory network globally, utilizing core reference laboratories to service samples from other states or countries to expand customer reach without an associated expansion in laboratory footprint. The company's strategy includes strengthening sales and marketing activities to reach customers and expand diagnostic and software use both in and outside the U.S.

IDEXX's gross profit margin increased by 80 basis points in 2025, reflecting benefits from recurring revenue growth in IDEXX VetLab consumable and reference laboratory testing volumes, along with operational productivity and pricing benefits, which offset impacts from higher product and labor costs due to inflationary cost effects. The company expects to continue to face higher costs for labor, commodities, energy, and transportation during 2026, as well as increased prices from suppliers and potential tariffs on imported goods. IDEXX aims to achieve cost improvements in its worldwide reference laboratory network by implementing global best practices, including lean processing techniques, technological enhancements, purchasing strategies, and consolidating testing in high volume laboratory hubs. The company also seeks cost improvements in the manufacture and service of point-of-care laboratory analyzers through economies of scale and improved instrument reliability.

IDEXX's projected capital expenditures for 2026 are estimated to be approximately $180.0 million , which includes capital investments in manufacturing and operations facilities to support growth, as well as investments in customer-facing software development. The company's research and development spending was $251.2 million for the year ended December 31, 2025. IDEXX has a share repurchase program with no specified expiration date, and as of December 31, 2025, there were 3,722,170 shares that may yet be purchased under the program. The company currently anticipates a 1% to 2% reduction in diluted shares through share repurchases in 2026. IDEXX has never declared or paid any cash dividends on its common stock and has no intention to declare or pay a dividend at this time.

IDEXX faces headwinds from macroeconomic and sector dynamics, including a decline in U.S. same-store clinical visits at veterinary practices of approximately 2% in 2025, impacted by ongoing veterinary practice capacity challenges and macroeconomic headwinds. The company's initial 2026 financial outlook anticipates a similar decline in U.S. same-store clinical growth levels. IDEXX also faces risks from changes in tariff and trade policies, as approximately 36% of overall revenues were attributable to sales to customers outside the U.S. for the year ended December 31, 2025. The company manufactures many products in the U.S. but relies on third-party suppliers in other regions for certain components, making it susceptible to tariffs and trade policy changes. Additionally, approximately 23% of consolidated revenue was derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies, exposing the company to foreign currency exchange rate fluctuations.

IDEXX faces constraints from supply chain and logistics challenges, including product and component availability issues, extended shipping periods, and inflationary cost pressures. The company purchases many products, components, and materials from sole or single sources, such as Ortho-Clinical Diagnostics, Inc. for certain Catalyst chemistry slides under supply agreements currently set to expire in December of 2044 . IDEXX also faces risks from consolidation in its customer base, as an increasing percentage of veterinary hospitals are owned by corporations, which could leverage buying power to obtain favorable pricing. The company's livestock and poultry products business is subject to fluctuations resulting from changes in disease prevalence, and disease outbreaks or successful eradication programs can significantly affect demand for certain products.

Risk Factors

IDEXX faces intense competition in the companion animal healthcare industry, and failure to successfully execute strategies such as developing innovative products, maintaining premium pricing, and achieving cost improvements could negatively impact growth and profitability. The company depends on third-party suppliers, including sole or single-source suppliers like Ortho-Clinical Diagnostics for Catalyst chemistry slides under agreements expiring in December of 2044 , and any disruption could materially affect the ability to supply customers. Consolidation in the veterinary customer base, including increased corporate hospital ownership, could lead to loss of business as corporate owners may shift purchases to competitors or operate their own reference laboratories. Changes in testing patterns due to vaccines, preventatives, or disease eradication could reduce demand for diagnostic tests. The company's international operations expose it to risks from foreign currency exchange rate fluctuations, with approximately 23% of consolidated revenue derived from products manufactured or sourced in U.S. dollars and sold internationally in local currencies, and a 1% strengthening of the U.S. dollar would reduce revenue by approximately $16 million and operating income by approximately $5 million , net of hedge positions. The company's use of AI in products and services presents risks including flawed algorithms, insufficient datasets, and evolving regulations such as the European Union Artificial Intelligence Act enacted in August 2024 .

Management Priorities

Management's message emphasizes IDEXX's strategy of providing veterinarians with the highest quality diagnostic information, software products and services, and medical evidence to support more advanced medical care and information management solutions. The company's forward-looking statements include expectations regarding global trends in companion animal healthcare and demand for products and services, future revenue growth rates, and the projected impact of foreign currency exchange rates and hedging activities. Management's strategic priorities for the period ahead include developing, manufacturing, and marketing innovative new or improved point-of-care laboratory analyzers that drive sales and grow the installed base of instruments; developing and introducing new or improved innovative diagnostic tests and services for reference laboratories and point-of-care applications; and developing and introducing new or improved innovative, data-insightful software solutions that enable veterinary customers to improve practice management and efficiency. The company also emphasizes achieving cost improvements in its worldwide reference laboratory network and in the manufacture and service of point-of-care laboratory analyzers, as well as continuing to expand and develop its companion animal diagnostic sales, marketing, customer support, and logistics organizations globally. Management's projected effective tax rate for 2026 is approximately 21.3% .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Recurring Diagnostic Revenue
  2. [2] Item 1, Business — Reference Laboratory Diagnostic and Consulting Services
  3. [3] Item 8, Note 3 — Revenue
  4. [4] Item 8, Note 3 — Revenue
  5. [5] Item 8, Note 3 — Revenue
  6. [6] Item 8, Note 3 — Revenue
  7. [7] Item 8, Note 3 — Revenue
  8. [8] Item 8, Note 3 — Revenue
  9. [9] Item 8, Note 3 — Revenue
  10. [10] Item 8, Note 3 — Revenue
  11. [11] Item 8, Note 3 — Revenue
  12. [12] Item 8, Note 3 — Revenue
  13. [13] Item 8, Note 3 — Revenue
  14. [14] Item 8, Note 3 — Revenue
  15. [15] Item 8, Note 4 — Acquisitions, Asset Purchases and Investments
  16. [16] Item 8, Note 4 — Acquisitions, Asset Purchases and Investments
  17. [17] Item 8, Note 4 — Acquisitions, Asset Purchases and Investments
  18. [18] Item 5, Purchases of Equity Securities by the Issuer
  19. [19] Item 8, Consolidated Statements of Cash Flows
  20. [20] Item 7, MD&A — Financing Activities
  21. [21] Item 7, MD&A — Financing Activities
  22. [22] Item 1, Business — Research and Development
  23. [23] Item 8, Consolidated Statements of Income
  24. [24] Item 7, MD&A — Total Company Revenue
  25. [25] Item 8, Consolidated Statements of Income
  26. [26] Item 8, Consolidated Statements of Income
  27. [27] Item 8, Consolidated Statements of Income
  28. [28] Item 8, Consolidated Statements of Income
  29. [29] Item 8, Consolidated Statements of Income
  30. [30] Item 7, MD&A — Gross Profit
  31. [31] Item 7, MD&A — Gross Profit
  32. [32] Item 8, Consolidated Statements of Income
  33. [33] Item 8, Consolidated Statements of Income
  34. [34] Item 8, Consolidated Statements of Cash Flows
  35. [35] Item 8, Consolidated Statements of Cash Flows
  36. [36] Item 7, MD&A — Provision for Income Taxes
  37. [37] Item 7, MD&A — Financing Activities
  38. [38] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  39. [39] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  40. [40] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  41. [41] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  42. [42] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  43. [43] Item 1, Business — Research and Development
  44. [44] Item 1A, Risk Factors — Since our business is global in nature
  45. [45] Item 7, MD&A — Gross Profit
  46. [46] Item 7, MD&A — Investing Activities
  47. [47] Item 5, Purchases of Equity Securities by the Issuer
  48. [48] Item 7, MD&A — CAG Trends
  49. [49] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  50. [50] Item 1, Business — Production and Supply
  51. [51] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  52. [52] Item 7A, Quantitative and Qualitative Disclosures About Market Risk
  53. [53] Item 1A, Risk Factors — Various U.S. and foreign government regulations
  54. [54] Item 8, Consolidated Balance Sheets
  55. [55] Item 8, Consolidated Balance Sheets
  56. [56] Item 7, MD&A — Financial Covenant
  57. [57] Item 7, MD&A — Provision for Income Taxes
  58. [58] Item 7, MD&A — Operating Expenses
  59. [59] Item 7, MD&A — Operating Expenses
  60. [60] Item 7, MD&A — Operating Expenses
  61. [61] Item 7, MD&A — Companion Animal Group
  62. [62] Item 7, MD&A — Companion Animal Group
  63. [63] Item 7, MD&A — Water
  64. [64] Item 7, MD&A — Water
  65. [65] Item 7, MD&A — Livestock, Poultry and Dairy
  66. [66] Item 7, MD&A — Livestock, Poultry and Dairy

Analysis on 6/8/2026